This study is testing a new medicine called **TTI-101** for people with a lung disease known as **Idiopathic Pulmonary Fibrosis (IPF)**, which causes scarring in the lungs and makes breathing difficult. The main goal is to see if taking TTI-101 daily by mouth for 12 weeks is safe and okay to use. To join, you need to have been diagnosed with IPF within the last 7 years. You must also meet certain breathing test criteria and have an oxygen level of at least 88% while resting. If you are on a medication called nintedanib, your dose must be stable for at least 3 months. **Key points to consider:** - **Study Length:** 12 weeks of treatment. - **Health Requirements:** No recent lung infections or planned surgeries during the study. - **Medication Restrictions:** No recent use of certain medications like pirfenidone and no smoking. Participants should not have other serious health conditions that could interfere with the study. This study could help understand if TTI-101 is safe and effective for managing IPF.